Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience

Hyperinflammation in COVID-19 plays a crucial role in pathogenesis and severity; thus, many immunomodulatory agents are applied in its treatment. We aimed to identify good clinical response predictors of tocilizumab (TCZ) treatment in severe COVID-19, among clinical, laboratory, and radiological var...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Wiktor, Pawlak-Buś, Katarzyna, Jóźwiak, Barbara, Leszczyński, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051490/
https://www.ncbi.nlm.nih.gov/pubmed/36983429
http://dx.doi.org/10.3390/jcm12062429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051490/
https://www.ncbi.nlm.nih.gov/pubmed/36983429
http://dx.doi.org/10.3390/jcm12062429

Ejemplares similares